Patents by Inventor William C. Lumma

William C. Lumma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of Visually Accenting a Piece of Jewelry
    Publication number: 20190373990
    Abstract: A method of visually accenting a piece of jewelry requires mounting a prominent decoration over an annular jewelry piece integrated with a plurality of inset ornaments. The method utilizes an annular jewelry piece, a plurality of prongs, a collar, and a prominent decoration. A plurality of inset ornaments is integrated into the jewelry piece. The prominent decoration is mounted over the plurality of ornaments by clearing a foundational surface from the outer surface. More specifically, the plurality of prongs is mounted into a plurality of mounting holes drilled into the foundational surface. The collar is then affixed onto the plurality of prongs, and the prominent decoration is affixed to the collar.
    Type: Application
    Filed: June 12, 2018
    Publication date: December 12, 2019
    Inventor: William C. Lumma
  • COMPOUNDS FOR MODULATING TRPV3 FUNCTION
    Publication number: 20170020858
    Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.
    Type: Application
    Filed: February 24, 2016
    Publication date: January 26, 2017
    Inventors: Jayhong A. Chong, Christopher Fanger, Glenn R. Larsen, William C. Lumma, JR., Magdalene M. Moran, Amy Ripka, Dennis John Underwood, Manfred Weigele, Xiaoguang Zhen
  • COMPOUNDS FOR MODULATING TRPV3 FUNCTION
    Publication number: 20150299225
    Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.
    Type: Application
    Filed: November 14, 2014
    Publication date: October 22, 2015
    Applicant: HYDRA BIOSCIENCES, INC.
    Inventors: Jayhong A. Chong, Christopher Fanger, Glenn R. Larsen, William C. Lumma, JR., Magdalene M. Moran, Amy Ripka, Dennis John Underwood, Manfred Weigele, Xiaoguang Zhen, Anu Mahadevan, Peter Meltzer
  • Compounds for modulating TRPV3 function
    Patent number: 8916550
    Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.
    Type: Grant
    Filed: November 15, 2006
    Date of Patent: December 23, 2014
    Assignee: Hydra Biosciences, Inc.
    Inventors: Jayhong A. Chong, Christopher Fanger, Glenn R. Larsen, William C. Lumma, Jr., Magdalene M. Moran, Amy Ripka, Dennis John Underwood, Manfred Weigele, Xiaoguang Zhen, Anu Mahadevan, Peter Meltzer
  • COMPOUNDS FOR MODULATING TRPV3 FUNCTION
    Publication number: 20140155417
    Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.
    Type: Application
    Filed: August 30, 2013
    Publication date: June 5, 2014
    Applicant: HYDRA BIOSCIENCES, INC.
    Inventors: Jayhong A. Chong, Christopher Fanger, Glenn R. Larsen, William C. Lumma, JR., Anu Mahadevan, Peter Meltzer, Magdalene M. Moran, Amy Ripka, Dennis Underwood, Manfred Weigele, Xiaoguang Zhen
  • Substituted pyrimido 4.5-d pyrimidin-4-one compounds for modulating TRPV3 function
    Patent number: 8552009
    Abstract: The present application relates to compounds of Formula I as defined herein, and methods for treating pain and other conditions related to TRPV3.
    Type: Grant
    Filed: February 7, 2011
    Date of Patent: October 8, 2013
    Inventors: Jayhong A. Chong, Christopher Fanger, Glenn R. Larsen, William C. Lumma, Jr., Magdalene M. Moran, Amy S. Ripka, Dennis John Underwood, Manfred Weigele, Xiaoguang Zhen, Anu Mahadevan, Peter Meltzer
  • Compounds for Modulating TRPV3 Function
    Publication number: 20110144135
    Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.
    Type: Application
    Filed: February 7, 2011
    Publication date: June 16, 2011
    Applicant: Hydra Biosciences, Inc.
    Inventors: Jayhong A. Chong, Christopher Fanger, Glenn R. Larsen, William C. Lumma, JR., Anu Mahadevan, Peter Meltzer, Magdalene M. Moran, Amy Ripka, Dennis John Underwood, Manfred Weigele, Xiaoguang Zhen
  • Substituted quinazolin-4-one compounds for antagonizing TRPV3 function
    Patent number: 7893260
    Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3. Suitable compounds include but are not limited to, for example, substituted quinazolin-4-ones of formula I.
    Type: Grant
    Filed: November 3, 2006
    Date of Patent: February 22, 2011
    Assignee: Hydra Biosciences, Inc.
    Inventors: Jayhong A. Chong, Christopher Fanger, Glenn R. Larsen, William C. Lumma, Jr., Magdalene M. Moran, Amy Ripka, Dennis John Underwood, Manfred Weigele, Xiaoguang Zhen
  • Compounds for Modulating TRPV3 Function
    Publication number: 20100273777
    Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.
    Type: Application
    Filed: April 6, 2010
    Publication date: October 28, 2010
    Applicant: Hydra Biosciences, Inc.
    Inventors: Jayhong A. Chong, Christopher Fanger, Glenn R. Larsen, William C. Lumma, JR., Magdalene M. Moran, Amy Ripka, Dennis John Underwood, Manfred Weigele, Xiaoguang Zhen
  • Compounds for modulating TRPV3 function
    Patent number: 7803790
    Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.
    Type: Grant
    Filed: May 9, 2006
    Date of Patent: September 28, 2010
    Assignee: Hydra Biosciences, Inc.
    Inventors: Jayhong A. Chong, Christopher Fanger, Glenn R. Larsen, William C. Lumma, Jr., Anu Mahadevan, Peter Meltzer, Magdalene M. Moran, Amy Ripka, Dennis John Underwood, Manfred Weigele, Xiaoguang Zhen
  • Compounds for Modulating TRPV3 Function
    Publication number: 20100152209
    Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.
    Type: Application
    Filed: November 3, 2006
    Publication date: June 17, 2010
    Applicant: Hydra Biosciences Inc.
    Inventors: Jayhong A. Chong, Christopher Fanger, Glenn R. Larsen, William C. Lumma, JR., Anu Mahadevan, Peter Meltzer, Magdalene M. Moran, Amy Ripka, Dennis John Underwood, Manfred Weigele, Xiaoguang Zhen
  • Tyrosine kinase inhibitors
    Patent number: 7265134
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: August 13, 2002
    Date of Patent: September 4, 2007
    Assignee: Merck & Co., Inc.
    Inventors: George D. Hartman, Thomas J. Tucker, John T. Sisko, Anthony M. Smith, William C. Lumma, Jr.
  • Tyrosine kinase inhibitors
    Patent number: 7115597
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: October 2, 2003
    Date of Patent: October 3, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, George D. Hartman, Jacob M. Hoffman, Jr., John T. Sisko, Peter J. Manley, Anthony M. Smith, Thomas J. Tucker, William C. Lumma, Jr., Leonard Rodman
  • Tyrosine kinase inhibitors
    Publication number: 20040242637
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: February 17, 2004
    Publication date: December 2, 2004
    Inventors: George D Hartman, Thomas J Tucker, John T Sisko, Anthony M Smith, William C Lumma
  • Tyrosine kinase inhibitors
    Publication number: 20040192926
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: February 11, 2004
    Publication date: September 30, 2004
    Inventors: George D. Hartman, Thomas J. Tucker, John T. Sisko, Anthony M. Smith, William C. Lumma Jr
  • Tyrosine kinase inhibitors
    Publication number: 20040063720
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: October 2, 2003
    Publication date: April 1, 2004
    Applicant: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, George D. Hartman, Jacob M. Hoffman, John T. Sisko, Peter J. Manley, Anthony M. Smith, Thomas J. Tucker, William C. Lumma, Leonard Rodman
  • Tyrosine kinase inhibitors
    Publication number: 20020137755
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: November 21, 2001
    Publication date: September 26, 2002
    Inventors: Mark T. Bilodeau, George D. Hartman, Jacob M. Hoffman, John T. Sisko, Peter J. Manley, Anthony M. Smith, Thomas J. Tucker, William C. Lumma, Leonard Rodman
  • Geranylgeranyl transferase inhibitor screening assay
    Publication number: 20020072081
    Abstract: The present invention is directed toward a GGTase-I competitive binding assay which can be used to determine the relative GGTase-I inhibitory potency of test compounds. The present invention is also directed toward radiolabeled geranylgeranyl-protein transferase type-I inhibitor compounds which are useful to label GGTase-I in assays, whether cell-based, tissue-based or in whole animal.
    Type: Application
    Filed: September 6, 2001
    Publication date: June 13, 2002
    Inventors: Wai-Si Eng, Robert B. Lobell, William C. Lumma, Anthony M. Smith
  • Inhibitors of prenyl-protein transferase
    Patent number: 6376496
    Abstract: The present invention comprises piperazine-containing compounds which inhibit prenyl-protein transferases, including farnesyl-protein transferase and geranylgeranyl-protein transferase type I. Such therapeutic compounds are useful in the treatment of cancer.
    Type: Grant
    Filed: March 1, 2000
    Date of Patent: April 23, 2002
    Assignee: Merck & Co., Inc.
    Inventors: George D. Hartman, William C. Lumma, Jr., John T. Sisko, Anthony M. Smith, Thomas J. Tucker, Jeffrey M. Bergman
  • Inhibitors of prenyl-protein transferase
    Patent number: 6358956
    Abstract: The present invention comprises piperazine-containing compounds which inhibit prenyl-protein transferases, including-farnesyl-protein transferase and geranylgeranyl-protein transferase type I. Such therapeutic compounds are useful in the treatment of cancer.
    Type: Grant
    Filed: March 1, 2000
    Date of Patent: March 19, 2002
    Assignee: Merck & Co., Inc.
    Inventors: George D. Hartman, William C. Lumma, Jr., John T. Sisko, Anthony M. Smith, Thomas J. Tucker, Gerald E. Stokker